The Company is a Japan-based biopharmaceutical products developer.
The Company is a Japan-based biopharmaceutical products developer. The Company develops biopharmaceutical products focused on the medication of cancer and other intractable diseases. It is engaged in the research, development, manufacture, and sale of anti-cancer drugs based on micellar nanoparticle technology. The Company's product candidates include Paclitaxel Micelle for the treatment of stomach cancer, Nanoplatin for the treatment of pancreatic cancer, and DACH-Platin Micelle for the treatment of solid cancer. The Company was established on June 14, 1996. Its share was listed on the Tokyo Stock Exchange Mothers on March 5, 2008.